Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The only substantive claim provided (“premature discontinuation of XARELTO increases the risk of thrombotic events”) is directly supported by the supplied FDA label excerpt (Section 5.1) with no contradictions identified.
Category Scores
Accurate Statements
Premature discontinuation of XARELTO increases the risk of thrombotic events.
Supported by SECTION: 5.1 Increased Risk of Thrombotic Events after Premature Discontinuation: 'Premature discontinuation of any oral anticoagulant, including XARELTO, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.'
Unsupported Statements
Contradictions
Important Omissions
The label conditions the increased thrombotic risk on discontinuation 'in the absence of adequate alternative anticoagulation'; the provided claim omits this qualifier.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim is label-supported and addresses a boxed-warning-adjacent safety concept (thrombotic risk after premature discontinuation). Minor omission of the label’s qualifying condition ('in the absence of adequate alternative anticoagulation') reduces precision but does not contradict the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of the label qualifier that the increased risk is in the absence of adequate alternative anticoagulation.
Suggested Improvement
State the claim with the label’s condition, e.g., 'Premature discontinuation of XARELTO (in the absence of adequate alternative anticoagulation) increases the risk of thrombotic events.'